CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
Status:
Recruiting
Trial end date:
2024-08-08
Target enrollment:
Participant gender:
Summary
This phase I trial studies best dose and side effects of CBL0137 in treating patients with
extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as
CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from
growing further.